|
AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
|
19 November 2024 |
|
Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
|
04 October 2024 |
|
Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
|
01 July 2024 |
|
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030
|
21 May 2024 |
|
AstraZeneca to acquire Amolyt Pharma, expanding late-stage rare disease pipeline
|
14 March 2024 |
|
Acquisition of Icosavax completed
|
19 February 2024 |
|
AstraZeneca to acquire Icosavax
|
12 December 2023 |
|
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
|
01 November 2023 |
|
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies
|
31 July 2023 |
|
AstraZeneca announces $400 million investment in reforestation and biodiversity in support of climate action and human health
|
17 July 2023 |